%0 Journal Article %T Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11) %A Gun Min Kim %A Hye Sook Han %A In Hae Park %A Jee Hyun Kim %A Ji-Yeon Kim %A Jin-Hee Ahn %A Joohyuk Sohn %A Keun Seok Lee %A Ki Hyeong Lee %A Korean Cancer Study Group %A Kyung Hae Jung %A Kyung-Hun Lee %A Se Hyun Kim %A Seock-Ah Im %A Seri Park %A Soo Jung Lee %A Sung-Bae Kim %A Tae-Yong Kim %A Yee Soo Chae %A Yeon Hee Park %A Young-Hyuck Im %J Archive of "Cancer Communications". %D 2019 %R 10.1186/s40880-019-0375-7 %X The online version of this article (10.1186/s40880-019-0375-7) contains supplementary material, which is available to authorized users %K Metastatic breast cancer %K Eribulin %K Paclitaxel %K Neuropathy %K Quality of life %K Functional assessment of cancer therapy-taxane questionnaires %U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540535/